SCHEMBL2369259

SCHEMBL2369259

CN(C)Cc1nc(C(N)c2ccccn2)c2c(-c3ccccc3)csc2n1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 8/20 0.41
ALDH1A1 P00352 6/20 0.41
KDM4E B2RXH2 4/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
SMN1; SMN2 Q16637 4/20 0.40
NPC1 O15118 1/20 0.40
HPGD P15428 1/20 0.40
CASP3 P42574 1/20 0.40
RAB9A P51151 1/20 0.40
SENP8 Q96LD8 1/20 0.40
SENP7 Q9BQF6 1/20 0.40
SENP6 Q9GZR1 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
DAPK3 O43293 1/20 0.39
PRKD3 O94806 1/20 0.39
MAP4K4 O95819 1/20 0.39
ABL1 P00519 1/20 0.39
NTRK1 P04629 1/20 0.39
LCK P06239 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3383431 0.89 ALDH1A1 (0.44) LMNAALDH1A1KDM4ESMN1; SMN2NPC1
SCHEMBL2368911 0.86 LMNA (0.45) LMNAALDH1A1KDM4ESMN1; SMN2NPC1
SCHEMBL2369496 0.86 MAPK1 (0.41) LMNAALDH1A1KDM4ESMN1; SMN2NPC1
SCHEMBL3384906 0.83 LMNA (0.39) LMNAALDH1A1KDM4EMEN1KMT2A
SCHEMBL2368941 0.81 LMNA (0.43) LMNAALDH1A1KDM4EKMT2ASMN1; SMN2
SCHEMBL3381246 0.81 LMNA (0.43) LMNAALDH1A1KDM4ESMN1; SMN2NPC1
SCHEMBL3387889 0.81 LMNA (0.50) LMNAALDH1A1KDM4ESMN1; SMN2NPC1
SCHEMBL2368668 0.79 LMNA (0.55) LMNAALDH1A1KDM4EMEN1KMT2A
SCHEMBL2368980 0.79 LMNA (0.40) LMNAALDH1A1KDM4EKMT2ASMN1; SMN2
SCHEMBL3387596 0.78 LMNA (0.42) LMNAALDH1A1KDM4ESMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1823071-B Thienopyrimidine derivatives as potassium channel inhibitors XENTION DISCOVERY LTD 2012-12-19 CN disclosed
US-8022076-B2 Thieno[2,3-d]pyrimidine derivatives as potassium channel modulators; antiarrhythmia agents XENTION LIMITED (GB) 2011-09-20 US disclosed
EP-1641803-B3 THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS XENTION LTD (GB) 2010-12-08 EP disclosed
EP-1641803-B1 THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS XENTION LTD (GB) 2009-03-18 EP disclosed
CN-1823071-A Thienopyrimidine derivatives as potassium channel inhibitors XENTION DISCOVERY LTD (GB) 2006-08-23 CN disclosed
EP-1641803-A1 THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS Xention Discovery Limited (GB) 2006-04-05 EP disclosed
US-20050026935-A1 Compounds XENTION DISCOVERY LTD. 2005-02-03 US disclosed
WO-2004111057-A1 THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS XENTION DISCOVERY LIMITED (GB) 2004-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050026935-A1 Compounds KCNJ11, KCNJ1, KCNH1 LMNA 1126/4885ALDH1A1 247/4885KDM4E 1880/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.